Literature DB >> 12572995

ICL670A: preclinical profile.

Hanspeter Nick1, Agnes Wong, Pierre Acklin, Bernard Faller, Yi Jin, René Lattmann, Thomas Sergejew, Suzanne Hauffe, Helmut Thomas, Hans Peter Schnebli.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12572995     DOI： 10.1007/978-1-4615-0593-8_10

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  21 in total

Review 1.  Deferasirox: oral, once daily iron chelator--an expert opinion.

Authors:  M B Agarwal
Journal:  Indian J Pediatr       Date:  2010-02-23       Impact factor: 1.967

2.  Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes.

Authors:  S Allegra; J Cusato; S De Francia; A Arduino; F Longo; E Pirro; D Massano; A De Nicolò; A Piga; A D'Avolio
Journal:  Pharmacogenomics J       Date:  2017-11-21       Impact factor: 3.550

Review 3.  Deferasirox nephrotoxicity-the knowns and unknowns.

Authors:  Juan Daniel Díaz-García; Angel Gallegos-Villalobos; Liliana Gonzalez-Espinoza; Maria D Sanchez-Niño; Jesus Villarrubia; Alberto Ortiz
Journal:  Nat Rev Nephrol       Date:  2014-07-22       Impact factor: 28.314

4.  Recent advances in the treatment of mucormycosis.

Authors:  Brad Spellberg; Ashraf S Ibrahim
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

5.  Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia.

Authors:  G Luo; B Spellberg; T Gebremariam; H Lee; Y Q Xiong; S W French; A Bayer; A S Ibrahim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-12-01       Impact factor: 3.267

6.  The iron chelator deferasirox protects mice from mucormycosis through iron starvation.

Authors:  Ashraf S Ibrahim; Teclegiorgis Gebermariam; Yue Fu; Lin Lin; Mohamed I Husseiny; Samuel W French; Julie Schwartz; Christopher D Skory; John E Edwards; Brad J Spellberg
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 7.  Recent advances in the management of mucormycosis: from bench to bedside.

Authors:  Brad Spellberg; Thomas J Walsh; Dimitrios P Kontoyiannis; John Edwards; Ashraf S Ibrahim
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

8.  Metabolically programmed iron chelators.

Authors:  Raymond J Bergeron; Neelam Bharti; James S McManis; Jan Wiegand
Journal:  Bioorg Med Chem       Date:  2015-06-29       Impact factor: 3.641

Review 9.  Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.

Authors:  Matt Shirley; Greg L Plosker
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

10.  Update on the use of deferasirox in the management of iron overload.

Authors:  Ali Taher; Maria Domenica Cappellini
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.